326 related articles for article (PubMed ID: 30837531)
1. Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil.
Taniguchi K; Ando Y; Nobori H; Toba S; Noshi T; Kobayashi M; Kawai M; Yoshida R; Sato A; Shishido T; Naito A; Matsuno K; Okamatsu M; Sakoda Y; Kida H
Sci Rep; 2019 Mar; 9(1):3466. PubMed ID: 30837531
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil.
Kiso M; Yamayoshi S; Furusawa Y; Imai M; Kawaoka Y
Viruses; 2019 Nov; 11(11):. PubMed ID: 31731678
[TBL] [Abstract][Full Text] [Related]
3. Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models.
Fukao K; Ando Y; Noshi T; Kitano M; Noda T; Kawai M; Yoshida R; Sato A; Shishido T; Naito A
PLoS One; 2019; 14(5):e0217307. PubMed ID: 31107922
[TBL] [Abstract][Full Text] [Related]
4. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.
Noshi T; Kitano M; Taniguchi K; Yamamoto A; Omoto S; Baba K; Hashimoto T; Ishida K; Kushima Y; Hattori K; Kawai M; Yoshida R; Kobayashi M; Yoshinaga T; Sato A; Okamatsu M; Sakoda Y; Kida H; Shishido T; Naito A
Antiviral Res; 2018 Dec; 160():109-117. PubMed ID: 30316915
[TBL] [Abstract][Full Text] [Related]
5. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.
Omoto S; Speranzini V; Hashimoto T; Noshi T; Yamaguchi H; Kawai M; Kawaguchi K; Uehara T; Shishido T; Naito A; Cusack S
Sci Rep; 2018 Jun; 8(1):9633. PubMed ID: 29941893
[TBL] [Abstract][Full Text] [Related]
6. PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor.
Luo D; Ye Q; Li RT; Zhou HY; Guo JJ; Zhao SQ; Zhang S; Jiang T; Deng YQ; Qin CF
Virol Sin; 2023 Aug; 38(4):559-567. PubMed ID: 37290559
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir
Mishin VP; Patel MC; Chesnokov A; De La Cruz J; Nguyen HT; Lollis L; Hodges E; Jang Y; Barnes J; Uyeki T; Davis CT; Wentworth DE; Gubareva LV
Emerg Infect Dis; 2019 Oct; 25(10):1969-1972. PubMed ID: 31287050
[TBL] [Abstract][Full Text] [Related]
8. Mutated influenza A virus exhibiting reduced susceptibility to baloxavir marboxil from an experimentally infected horse.
Nemoto M; Tamura N; Bannai H; Tsujimura K; Kokado H; Ohta M; Yamanaka T
J Gen Virol; 2019 Nov; 100(11):1471-1477. PubMed ID: 31526451
[TBL] [Abstract][Full Text] [Related]
9. Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018.
Koszalka P; Tilmanis D; Roe M; Vijaykrishna D; Hurt AC
Antiviral Res; 2019 Apr; 164():91-96. PubMed ID: 30771405
[TBL] [Abstract][Full Text] [Related]
10. Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility.
Jones JC; Pascua PNQ; Fabrizio TP; Marathe BM; Seiler P; Barman S; Webby RJ; Webster RG; Govorkova EA
Proc Natl Acad Sci U S A; 2020 Apr; 117(15):8593-8601. PubMed ID: 32217734
[TBL] [Abstract][Full Text] [Related]
11. The active form of the influenza cap-snatching endonuclease inhibitor baloxavir marboxil is a tight binding inhibitor.
Todd B; Tchesnokov EP; Götte M
J Biol Chem; 2021; 296():100486. PubMed ID: 33647314
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection.
Taniguchi K; Ando Y; Kobayashi M; Toba S; Nobori H; Sanaki T; Noshi T; Kawai M; Yoshida R; Sato A; Shishido T; Naito A; Matsuno K; Okamatsu M; Sakoda Y; Kida H
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062315
[TBL] [Abstract][Full Text] [Related]
13. The impact of PA/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza A viruses to baloxavir.
Taniguchi K; Noshi T; Omoto S; Sato A; Shishido T; Matsuno K; Okamatsu M; Krauss S; Webby RJ; Sakoda Y; Kida H
Arch Virol; 2024 Jan; 169(2):29. PubMed ID: 38216710
[TBL] [Abstract][Full Text] [Related]
14. [Baloxavir marboxil: a potent cap-dependent endonuclease inhibitor of influenza viruses].
Reina J; Reina N
Rev Esp Quimioter; 2019 Feb; 32(1):1-5. PubMed ID: 30676002
[TBL] [Abstract][Full Text] [Related]
15. Baloxavir marboxil: the new influenza drug on the market.
O'Hanlon R; Shaw ML
Curr Opin Virol; 2019 Apr; 35():14-18. PubMed ID: 30852344
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection.
Fukao K; Noshi T; Yamamoto A; Kitano M; Ando Y; Noda T; Baba K; Matsumoto K; Higuchi N; Ikeda M; Shishido T; Naito A
J Antimicrob Chemother; 2019 Mar; 74(3):654-662. PubMed ID: 30476172
[TBL] [Abstract][Full Text] [Related]
17. The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets.
Kitano M; Matsuzaki T; Oka R; Baba K; Noda T; Yoshida Y; Sato K; Kiyota K; Mizutare T; Yoshida R; Sato A; Kamimori H; Shishido T; Naito A
Influenza Other Respir Viruses; 2020 Nov; 14(6):710-719. PubMed ID: 32533654
[TBL] [Abstract][Full Text] [Related]
18. Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains.
Checkmahomed L; M'hamdi Z; Carbonneau J; Venable MC; Baz M; Abed Y; Boivin G
J Infect Dis; 2020 Jan; 221(1):63-70. PubMed ID: 31419295
[TBL] [Abstract][Full Text] [Related]
19. Influenza A virus polymerase acidic protein E23G/K substitutions weaken key baloxavir drug-binding contacts with minimal impact on replication and transmission.
Jones JC; Zagribelnyy B; Pascua PNQ; Bezrukov DS; Barman S; Okda F; Webby RJ; Ivanenkov YA; Govorkova EA
PLoS Pathog; 2022 Jul; 18(7):e1010698. PubMed ID: 35830486
[TBL] [Abstract][Full Text] [Related]
20. Baloxavir heralds a new era in influenza virus biology.
Kikuchi T; Watanabe A
Respir Investig; 2019 Jan; 57(1):1-2. PubMed ID: 30396860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
